WebDoctor Encyclopedia

Article

Stereotactic Radiosurgery (SRS)

What is stereotactic radiosurgery?

Stereotactic radiosurgery (SRS) is a highly focused form of radiotherapy used to treat small tumours and other targets inside the brain. Despite the name, there is no cutting. Instead, many narrow beams of radiation converge on the target from different directions, delivering a high dose to the tumour while sparing the surrounding brain.

SRS is usually given in a single session. When the dose is split over 2-5 sessions, the treatment is often called fractionated stereotactic radiotherapy or hypofractionated SRS. Both work on the same principle of extreme precision.

The most common use of SRS is for brain metastases: cancer that has spread to the brain from elsewhere, such as the lung, breast, kidney or skin. It is also used for some non-cancerous brain tumours, such as meningiomas, vestibular schwannomas (acoustic neuromas) and pituitary tumours, and for certain non-cancer conditions.

Precision is achieved through detailed MRI scans, careful planning and either a lightweight frame attached to the head or a close-fitting mask, so that the head stays perfectly still during treatment. The equivalent technique for tumours in the rest of the body is called stereotactic body radiotherapy and is covered in a separate article.

A brief history

In 1951, the Swedish neurosurgeon Lars Leksell proposed treating targets deep in the brain with focused radiation instead of open surgery. His work led to the first Gamma Knife in the late 1960s. From the 1980s, linear accelerators were adapted for radiosurgery, and frameless systems using masks and image guidance followed. Today, radiosurgery is available in many cancer centres and has largely replaced whole-brain radiotherapy for people with a limited number of brain metastases.

1. Key facts at a glance

Feature Details
Type of treatment Stereotactic external beam radiotherapy to the brain
Main uses Brain metastases, meningioma, vestibular schwannoma, pituitary tumours
How it is given Many beams focused on the target while the head is held still by a frame or mask
Number of sessions Usually 1; sometimes 2-5
Session length From about 20 minutes to a few hours, depending on the machine and number of targets
Hospital stay Usually none; most people go home the same day
Common side effects Tiredness, headache, mild nausea; later swelling or radiation necrosis

2. How it works

Focusing the dose

Each beam on its own passes through the brain at a low dose. Where all the beams meet, the dose is very high. Because the dose falls off steeply at the edge of the target, healthy brain tissue only millimetres away receives much less. The high dose damages the DNA of tumour cells and the blood vessels that feed them, causing the tumour to stop growing or shrink over weeks to months.

Machines used

System How it works
Gamma Knife About 200 cobalt-60 sources arranged in a helmet-shaped unit; traditionally used with a head frame, now often with a mask
Linear accelerator (LINAC) Standard radiotherapy machine with specialised collimators and image guidance
CyberKnife Compact linear accelerator on a robotic arm with continuous image tracking

Each type can achieve excellent precision. The best system depends on the target, its size and location, and what is available locally.

Why avoid whole-brain radiotherapy?

Whole-brain radiotherapy treats the entire brain and can reduce the chance of new metastases appearing. However, it often affects memory and thinking. SRS treats only the visible tumours, protecting brain function, with regular MRI scans to catch any new spots early.

3. Who it is for

Conditions treated

Condition Role of SRS
Non-small cell lung cancer One of the most common sources of brain metastases
Small cell lung cancer Selected people with a limited number of brain metastases
HER2-positive breast cancer Brain metastases are relatively common in this subtype
Triple-negative breast cancer Brain metastases
Melanoma Brain metastases, often alongside immunotherapy
Clear cell renal cell carcinoma Brain metastases, which respond poorly to standard radiotherapy
Meningioma Small tumours or residual tumour after surgery
Vestibular schwannoma Small to medium tumours, as an alternative to surgery
Pituitary tumours Residual or recurrent tumours after surgery

SRS after surgery

When a brain metastasis is removed by surgery, cancer cells may remain around the edge of the cavity. Giving SRS to the surgical cavity, usually within a few weeks of the operation, lowers the chance of the tumour returning there. This approach has also largely replaced whole-brain radiotherapy after surgery in many centres.

Non-cancerous tumours

For benign tumours such as meningiomas and vestibular schwannomas, the aim of SRS is to stop the tumour growing rather than to make it disappear. Many tumours stay the same size for years after treatment, which counts as success. Lower doses are used than for metastases, to protect nearby nerves such as those controlling hearing, facial movement and vision.

Who is suitable

Factor Typical considerations
Number of tumours Traditionally 1-4, but increasingly up to 10 or more
Size Usually under about 3-4 cm; larger tumours may be treated in several sessions
Location Tumours near the optic nerves or brainstem need special care
Overall health Expected to benefit from local control of brain disease
Symptoms Large tumours causing pressure may need surgery first

4. Before treatment

Step Why it is done
Consultation With a neurosurgeon and radiation oncologist
MRI with contrast High-resolution scan to define every target
CT scan Used for planning
Mask or frame Mask made in advance, or frame fitted on the treatment day
Steroids Sometimes given to reduce swelling
Medicine review Blood thinners and seizure medicines checked
Planning Physicists design the beam arrangement, often over several days

5. What to expect: step by step

Step What happens
1. Frame fitting (if used) A light frame is fixed to the head with local anaesthetic at four points
2. Imaging Scans confirm the target position
3. Positioning You lie on the couch with your head secured
4. Treatment The machine delivers the beams; you feel nothing and can usually listen to music
5. Monitoring Staff watch you on camera and can talk to you at any time
6. Finishing The frame or mask is removed
7. Going home Usually the same day, with someone to accompany you

If a frame is used, there may be some soreness or small marks where the pins were placed, which heal within days.

6. Side effects and risks

Side effect When Notes
Tiredness Days to weeks Usually mild
Headache Hours to days Simple painkillers usually help
Nausea First day Uncommon
Seizures Rarely, soon after More likely if seizures have occurred before
Swelling (oedema) Weeks to months Can cause symptoms; treated with steroids
Radiation necrosis Months to years Area of dead tissue that can mimic tumour growth; may need steroids, bevacizumab or surgery
Hair loss Weeks Small patches, only if the target is near the scalp
Hearing changes Months to years After treatment of vestibular schwannoma

Radiation necrosis

Radiation necrosis is the most important late side effect. It occurs when healthy tissue around the treated area is damaged. It may cause no symptoms or may cause headache, weakness or seizures.

On scans, it can look like a returning tumour, so specialised MRI or PET scans, or sometimes surgery, are used to tell the two apart. The risk is higher for larger targets and when SRS is combined with certain drugs.

7. Results and outlook

Study Main finding
N0574, 1-3 brain metastases (213 people) Cognitive decline at 3 months was much less common after SRS alone (64%) than with added whole-brain radiotherapy (92%), with better quality of life and similar survival (Brown et al., 2016)
MD Anderson trial, 1-3 brain metastases (58 people) Adding whole-brain radiotherapy to SRS led to more decline in learning and memory at 4 months, although it reduced new brain metastases (Chang et al., 2009)
JLGK0901, up to 10 brain metastases (1,194 people) Survival after SRS alone was similar for people with 5-10 tumours and those with 2-4 tumours, and side effects were uncommon (Yamamoto et al., 2014)

What the evidence means

For people with a limited number of brain metastases, SRS alone is now preferred over SRS plus whole-brain radiotherapy, because it protects memory and quality of life without shortening survival. The trade-off is a higher chance of new brain metastases, which is why regular MRI scans are so important. When new spots appear, they can often be treated with SRS again.

8. Recovery and aftercare

After treatment

Tip Why
Rest for the rest of the day Tiredness is common
Do not drive yourself home Driving rules after brain tumours vary; check with your team
Take steroids as prescribed Do not stop suddenly
Report new headache, weakness or confusion Possible swelling
Report a seizure immediately Needs urgent assessment

Follow-up

Check Timing
MRI scans Usually every 2-3 months for the first year
Clinic review To discuss results and symptoms
Hearing tests After treatment of vestibular schwannoma
Hormone tests After treatment of pituitary tumours

Caring for someone after radiosurgery

Family members can help by watching for changes in behaviour, speech or movement, and by keeping a list of medicines and scan dates. If you notice sudden confusion, weakness or a seizure, seek urgent medical help.

Driving

Most countries have rules about driving after a brain tumour or seizure. You may need to inform the licensing authority and stop driving for a period. Your team can explain what applies to you.

Living with brain metastases

A diagnosis of brain metastases can be frightening. Advances in treatment mean that many people now live for longer with good quality of life, especially those with targeted or immunotherapy options. Talking openly with your team, and accessing psychological support, can help you plan and cope.

Combining SRS with drug treatments

Many people with brain metastases also receive drug treatments for their cancer elsewhere in the body. Some targeted drugs and immune checkpoint inhibitors also reach the brain. Your team will decide how to time SRS around these treatments to get the most benefit and keep side effects low.

9. Alternatives

Alternative When it is considered
Surgery Large tumours, tumours causing pressure, or when a diagnosis is needed
Whole-brain radiotherapy Many brain metastases, or when SRS is not possible
Proton beam therapy Some skull base tumours
Palliative radiotherapy Simple courses for symptom control
Drug treatment alone Small, symptom-free metastases in cancers with brain-penetrating drugs
Active monitoring Small, slow-growing benign tumours

10. Frequently asked questions

Question Answer
Is radiosurgery an operation? No, there is no cutting; it is a type of radiotherapy
Will I lose my hair? Usually not, or only in small patches
Does it hurt? The treatment itself is painless; frame pins cause brief discomfort
Can it be repeated? Yes, new tumours can usually be treated
When will I know if it worked? Tumours often shrink over months; the first MRI is usually 2-3 months after
Will it affect my memory? Much less than whole-brain radiotherapy
Can I have it with immunotherapy? Often, with careful planning

11. Questions to ask your care team

  • Why is SRS recommended for me rather than surgery or whole-brain radiotherapy?
  • Will I have a frame or a mask?
  • How many sessions will I need?
  • What side effects should I watch for?
  • How often will I need MRI scans?
  • What happens if new tumours appear?
  • Can I drive after treatment?

Resources

  1. Brown, P.D. et al. (2016) ‘Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial’, JAMA, 316(4), pp. 401-409.
  2. Chang, E.L. et al. (2009) ‘Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial’, The Lancet Oncology, 10(11), pp. 1037-1044.
  3. Yamamoto, M. et al. (2014) ‘Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study’, The Lancet Oncology, 15(4), pp. 387-395.
  4. National Cancer Institute (2026) Central Nervous System Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq (Accessed: October 2026).
  5. National Cancer Institute (2026) External Beam Radiation Therapy for Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/external-beam (Accessed: October 2026).

Prepared by the editorial team, October 2026.